Susanne Sebens

4.2k total citations
102 papers, 3.1k citations indexed

About

Susanne Sebens is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Susanne Sebens has authored 102 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 61 papers in Oncology, 39 papers in Molecular Biology and 36 papers in Immunology. Recurrent topics in Susanne Sebens's work include Pancreatic and Hepatic Oncology Research (34 papers), Cancer Cells and Metastasis (26 papers) and Cancer Immunotherapy and Biomarkers (13 papers). Susanne Sebens is often cited by papers focused on Pancreatic and Hepatic Oncology Research (34 papers), Cancer Cells and Metastasis (26 papers) and Cancer Immunotherapy and Biomarkers (13 papers). Susanne Sebens collaborates with scholars based in Germany, United States and Poland. Susanne Sebens's co-authors include H. Schäfer, Hendrik Ungefroren, Alexander Arlt, Claudia Geismann, Ole Helm, Hendrik Lehnert, Christoph Röcken, Dieter Kabelitz, Janka Held‐Feindt and Daniela Wesch and has published in prestigious journals such as Journal of Biological Chemistry, SHILAP Revista de lepidopterología and Gastroenterology.

In The Last Decade

Susanne Sebens

100 papers receiving 3.1k citations

Peers

Countries citing papers authored by Susanne Sebens

Since Specialization

Citations

This map shows the geographic impact of Susanne Sebens's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Susanne Sebens with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Susanne Sebens more than expected).

Fields of papers citing papers by Susanne Sebens

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Susanne Sebens. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Susanne Sebens. The network helps show where Susanne Sebens may publish in the future.

Co-authorship network of co-authors of Susanne Sebens

This figure shows the co-authorship network connecting the top 25 collaborators of Susanne Sebens. A scholar is included among the top collaborators of Susanne Sebens based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Susanne Sebens. Susanne Sebens is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Transmembrane Protease Serine 11B Modulates Lactate Transport Through SLC16A1 in Pancreatic Ductal Adenocarcinoma—A Functional Link to Phenotype Heterogeneity 2025 ·International Journal of Molecular Sciences ·(unknown), (unknown), Claudia Geismann, Christoph Röcken, Eric Beitz, Susanne Sebens, Anna Trauzold, H. Schäfer	1
2	Epithelial and Mesenchymal-like Pancreatic Cancer Cells Exhibit Different Stem Cell Phenotypes Associated with Different Metastatic Propensities 2024 ·Cancers ·(unknown), (unknown), (unknown), Axel Künstner, Anne‐Sophie Mehdorn, Charlotte A. E. Hauser, (unknown), Olga Will, Patrick Hoffmann, (unknown), Sören Franzenburg, (unknown), Udo Schumacher, Hauke Busch, Susanne Sebens	4
3	Monocarboxylate Transporter-1 (MCT1)-Mediated Lactate Uptake Protects Pancreatic Adenocarcinoma Cells from Oxidative Stress during Glutamine Scarcity Thereby Promoting Resistance against Inhibitors of Glutamine Metabolism 2023 ·Antioxidants ·(unknown), (unknown), Claudia Geismann, Christian Röder, Timo Gemoll, Susanne Sebens, Anna Trauzold, H. Schäfer	9
4	Sequential Treatment with Temozolomide Plus Naturally Derived AT101 as an Alternative Therapeutic Strategy: Insights into Chemoresistance Mechanisms of Surviving Glioblastoma Cells 2023 ·International Journal of Molecular Sciences ·(unknown), (unknown), (unknown), (unknown), Ottmar Janßen, (unknown), Fabian Schütt, Rainer Adelung, Ralph Lucius, Jochen Haag, Susanne Sebens, Michael Synowitz, Janka Held‐Feindt	1
5	Hepatic myofibroblasts exert immunosuppressive effects independent of the immune checkpoint regulator PD-L1 in liver metastasis of pancreatic ductal adenocarcinoma 2023 ·Frontiers in Oncology ·(unknown), (unknown), (unknown), Sandra Krüger, S. Heckl, Daniela Wesch, H. Schäfer, Christoph Röcken, Sascha Rahn, Susanne Sebens	6
6	Utilizing Sphingomyelinase Sensitizing Liposomes in Imaging Intestinal Inflammation in Dextran Sulfate Sodium-Induced Murine Colitis 2022 ·Biomedicines ·(unknown), Jie Pan, (unknown), (unknown), (unknown), Olga Will, Susanne Sebens, Oula Peñate Medina	6
7	The Microbiome Tumor Axis: How the Microbiome Could Contribute to Clonal Heterogeneity and Disease Outcome in Pancreatic Cancer 2021 ·Frontiers in Oncology ·(unknown), (unknown), John F. Baines, Susanne Sebens	10
8	Pitfalls in the characterization of circulating and tissue-resident human γδ T cells 2020 ·Journal of Leukocyte Biology ·(unknown), Daniela Wesch, Hans‐Heinrich Oberg, Christian Peters, (unknown), Benjamin Weide, Claus Garbe, Graham Pawelec, Susanne Sebens, Christoph Röcken, Hisayoshi Hashimoto, Markus Löffler, (unknown), Shahram Kordasti, Dieter Kabelitz, Karin Schilbach, Kilian Wistuba‐Hamprecht	11
9	Utilizing ICG Spectroscopical Properties for Real-Time Nanoparticle Release Quantification In vitro and In vivo in Imaging Setups 2020 ·Current Pharmaceutical Design ·(unknown), (unknown), (unknown), (unknown), Hanwen Zhu, (unknown), (unknown), (unknown), (unknown), Olga Will, Yahya Açil, Kalevi Kairemo, Jörg Wiltfang, Claus‐C. Glüer, Regina Scherließ, Susanne Sebens, Oula Peñate Medina	4
10	Alpha-MSH Targeted Liposomal Nanoparticle for Imaging in Inflammatory Bowel Disease (IBD) 2020 ·Current Pharmaceutical Design ·(unknown), (unknown), Miriam Benezra, Olga Will, Kalevi Kairemo, (unknown), Susanne Sebens, Oula Peñate Medina	11
11	Entry and exit of chemotherapeutically-promoted cellular dormancy in glioblastoma cells is differentially affected by the chemokines CXCL12, CXCL16, and CX3CL1 2020 ·Oncogene ·(unknown), Kirsten Hattermann, (unknown), (unknown), Ralph Lucius, Michael Synowitz, Susanne Sebens, Janka Held‐Feindt	26
12	Tribody [(HER2)2xCD16] Is More Effective Than Trastuzumab in Enhancing γδ T Cell and Natural Killer Cell Cytotoxicity Against HER2-Expressing Cancer Cells 2018 ·Frontiers in Immunology ·Hans‐Heinrich Oberg, Christian Kellner, (unknown), Susanne Sebens, Dirk Bauerschlag, Martin Gramatzki, Dieter Kabelitz, Matthias Peipp, Daniela Wesch	80
13	Nuclear factor E2-related factor-2 has a differential impact on MCT1 and MCT4 lactate carrier expression in colonic epithelial cells: a condition favoring metabolic symbiosis between colorectal cancer and stromal cells 2017 ·Oncogene ·K. Diehl, (unknown), Ole Helm, (unknown), (unknown), Alexander Arlt, Christoph Röcken, Susanne Sebens, H. Schäfer	42
14	Colonic Lamina Propria Inflammatory Cells from Patients with IBD Induce the Nuclear Factor-E2 Related Factor-2 Thereby Leading to Greater Proteasome Activity and Apoptosis Protection in Human Colonocytes 2016 ·Inflammatory Bowel Diseases ·Marie‐Luise Kruse, Martin G. Friedrich, Alexander Arlt, Christoph Röcken, Jan-Hendrik Egberts, Susanne Sebens, H. Schäfer	23
15	Negative control of TRAIL-R1 signaling by transforming growth factor β1 in pancreatic tumor cells involves Smad-dependent down regulation of TRAIL-R1 2016 ·Cellular Signalling ·(unknown), Hendrik Ungefroren, Ole Helm, (unknown), (unknown), (unknown), Sebastian Hübner, (unknown), Susanne Sebens, Dieter Adam, Holger Kalthoff, Anna Trauzold	11
16	γδ T cell activation by bispecific antibodies 2015 ·Cellular Immunology ·Hans‐Heinrich Oberg, Christian Kellner, (unknown), Matthias Peipp, Christian Peters, Susanne Sebens, Dieter Kabelitz, Daniela Wesch	41
17	Novel Bispecific Antibodies Increase γδ T-Cell Cytotoxicity against Pancreatic Cancer Cells 2014 ·Cancer Research ·Hans‐Heinrich Oberg, Matthias Peipp, Christian Kellner, Susanne Sebens, Sarah Krause, (unknown), Sabine Adam‐Klages, Christoph Röcken, Thomas Becker, Ilka Vogel, D. Weisner, Sandra Freitag‐Wolf, Martin Gramatzki, Dieter Kabelitz, Daniela Wesch	126
18	M1 and M2: there is no “good” and “bad”—How macrophages promote malignancy-associated features in tumorigenesis 2014 ·OncoImmunology ·Ole Helm, Janka Held‐Feindt, H. Schäfer, Susanne Sebens	33
19	L1CAM promotes enrichment of immunosuppressive T cells in human pancreatic cancer correlating with malignant progression 2014 ·Molecular Oncology ·Evelin Grage‐Griebenow, (unknown), (unknown), Daniel Wicklein, Daniela Wesch, Sandra Freitag‐Wolf, Lisa Goebel, Ilka Vogel, Thomas Becker, Michael Ebsen, Christoph Röcken, Peter Altevogt, Udo Schumacher, H. Schäfer, Susanne Sebens	39
20	NF-κ B as a Molecular Target in the Therapy of Pancreatic Carcinoma 2007 ·PubMed ·Susanne Sebens, Alexander Arlt, H. Schäfer	31

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact